A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.
Lymphoma
DRUG: 6MW3211
Objective response rate, Defined as the percentage of subjects who experience a best response of either CR or PR, 1 Year
Complete response rate, Defined as the percentage of subjects who experience a best response of CR, 1 Year|Duration of response, Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause, 1 Year|Time to response, Time from the date of first infusion to the date of confirmed CR or PR, 1 Year|Progression free survival, Time from the date of first infusion to the earliest date of documented disease progression per radiological evidence or death from any cause, 1 Year|Overall survival, Time from the date of first infusion until the date of death from any cause, 1 Year|Incidence of adverse events, Up to 28 days post last dose|PK Parameter, Maximum concentration (Cmax), 1 Year
This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.